A multicenter, randomized, double-blind, placebo-controlled phase II/III clinical study of STI-004 (a biosimilar antibody for Omalizumab (Xolair®), in adult and adolescent patients suffering from allergic asthma

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled phase II/III clinical study of STI-004 (a biosimilar antibody for Omalizumab (Xolair®), in adult and adolescent patients suffering from allergic asthma

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 May 2016 New trial record
    • 16 May 2016 Results published in the Sorrento Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top